Kolon Life Science, Inc.

The Korea Exchange has decided to maintain the stock listing of Kolon TissueGene, Inc. , which has resumed trading on the Kosdaq market after the domestic bioventure fulfilled business improvement co

Scrip regularly covers business development and deal-making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Juniper Acquires Kolon’s Cell-Mediated

While global pharma firms are rolling out advanced gene and cell therapies, as well as aggressively making R&D investments in the space to grab the leading position in the burgeoning market, South Kor

2019 was a challenging year for the South Korean pharma and biotech sector. On balance, negative and disappointing news outnumbered positive developments, amid issues regarding the country’s first app